Developer docs
API playgroundTry for free, no card

Search company profiles

Poietis

Full company profile

uuid0003ks4

Namestring
Poietis
Legal namestring
Poietis SAS
Websiteurl
poietis.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Poietis is a French biotechnology company founded in 2014 in Pessac (Bordeaux Métropole) that develops and commercializes laser-assisted bioprinting (LAB) platforms for fabricating living human tissue. Its core technology is rooted in Laser-Induced Forward Transfer (LIFT), licensed exclusively from Inserm and the University of Bordeaux, and delivers picoliter-scale, nozzle-free cell deposition with >95% post-print viability at cellular resolution (10–50 µm). The company's flagship offering is the NGB (Next Generation Bioprinting) platform, available in two versions: NGB-R for research use and NGB-C, a GMP-compliant, Class II biosafety-cabinet-integrated system for clinical manufacturing of implantable tissues. The platform combines laser, extrusion, microvalve, and UV polymerization heads on a Stäubli 6-axis robotic arm, with optional add-on modules (PickCell for image-guided spheroid pick-and-place and ViewPrint for in-line microscope-based adaptive patterning). Poietis also sells Poieskin, positioned as the first commercially available bioprinted human skin substitute.

Poietis operates a multi-revenue-stream business model: capital equipment sales (NGB-R and NGB-C bioprinters under quote-based enterprise contracts), one-time sale of bioprinted tissue products (Poieskin), licensing/royalties on its licensed Inserm/University of Bordeaux technology, and fee-for-service research collaborations. Its go-to-market combines direct enterprise sales with event-driven demand generation at TERMIS, ISBF, and Biofabrication conferences, and selective channel distribution (HVD Life Science for Austria and Germany). The company is organized to serve pharmaceutical and dermo-cosmetic R&D buyers (BASF, L'Oréal, Servier), hospital ATMP manufacturers (AP-HM Marseille — site of the world's first GMP bioprinter installation), and academic research consortia (KU Leuven Prometheus, 3d.FAB). The firm is privately held, backed by approximately €6 million in disclosed equity and non-dilutive funding, employs 30–35 people, and operates a portfolio of 70+ patents.

Short descriptiontext

Poietis is a French biotechnology company that develops laser-assisted bioprinting platforms (NGB-R for research, NGB-C for clinical/GMP use) and the Poieskin bioprinted skin substitute, serving pharmaceutical, dermo-cosmetic, and hospital ATMP customers including BASF, L'Oréal, Servier, and AP-HM.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPessac, France
HQ citystring
Pessac
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
laser-assisted bioprinting, 3D tissue engineering, bioprinting platforms, regenerative medicine, in vitro tissue models
Industry5 codes
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAADAG
Medical & Dental 3D Printing Services (patient-specific devices, dental labs)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Services (On-Demand Manufacturing & Service Bureaus)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical Appliance and Supplies Manufacturing339113
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Bioprinting Equipment and Tissue Engineering
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Bioprinter Sales (NGB-R and NGB-C)
TypeHardware Sales
Description

Sale of NGB bioprinting platforms - both research version (NGB-R) for academic and pharmaceutical R&D, and clinical version (NGB-C) for hospitals and cell therapy manufacturing centers. Revenue from capital equipment sales with typical enterprise sales cycle.

poietis.com
2Bioprinted Tissue Products (Poieskin)
TypeOne Time License
Description

Sale of bioprinted tissue products including Poieskin, the first commercially available bioprinted human tissue. Used by pharmaceutical companies for drug testing and cosmetics companies for ingredient testing.

poietis.com
3Technology Licensing
TypeLicensing Royalties
Description

Exclusive worldwide license to bioprinting technology developed at Inserm and University of Bordeaux. Technology licensing for commercial applications in tissue engineering and regenerative medicine.

poietis.com
4Research Partnerships and Collaborations
TypeProfessional Services
Description

Fee-for-service research collaborations with pharmaceutical and cosmetic companies for development of specific tissue models, toxicology testing, and drug discovery applications.

poietis.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1NGB (Next Generation Bioprinting)
Description

Multimodal bioprinting platform available in research (NGB-R) and clinical (NGB-C) versions, integrating laser, extrusion, and microvalve bioprinting technologies.

poietis.com
+3 more records
Core offering1 text field

Poietis designs and manufactures the NGB (Next Generation Bioprinting) robotic bioprinting platform available in two versions: NGB-R for research applications and NGB-C for clinical/GMP-compliant manufacturing of implantable tissues. The platform integrates laser-assisted bioprinting with extrusion, microvalve, and UV-curing technologies on a 6-axis robotic arm. Poietis also produces Poieskin, the first commercially available bioprinted human tissue product used for pharmaceutical testing, cosmetics evaluation, and clinical wound healing applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Cell viability post-printing maintained above 95%
+3 more records
Product overview1 text field

Poietis offers a modular bioprinting platform architecture anchored by the NGB (Next Generation Bioprinting) system, available in two versions: NGB-R™ for research use and NGB-C™ for clinical/GMP manufacturing. The platform is multimodal, combining laser-assisted bioprinting (LAB) with extrusion, microvalve, and UV-curing heads on a robotic 6-axis arm, and supports add-on modules including ViewPrint™ (in-line microscope for real-time pattern adaptation) and PickCell™ (image-guided spheroid pick-and-place). The commercial tissue product Poieskin® — the first bioprinted tissue to reach the market — is produced using this technology. The portfolio spans from in vitro tissue models for pharmaceutical and dermo-cosmetic testing to implantable Advanced Therapy Medicinal Products (ATMPs) for regenerative medicine.

Product and service4 records
1NGB-R™ (Next Generation Bioprinting – Research)
CategoryBioprinting Platform
Description

A robotic bioprinting platform for research applications in oncology, 3D tissue disease models, and translational research. It combines laser-assisted bioprinting (LAB) with extrusion and microvalve heads, a 6-axis robotic arm, and an in-line microscope, enabling high-precision, automated 3D tissue fabrication with cellular resolution.

2NGB-C™ (Next Generation Bioprinting – Clinical)
CategoryClinical Bioprinting Platform
Description

A GMP-compliant, clinical-grade robotic bioprinting platform for manufacturing implantable bioprinted tissues in hospital ATMP manufacturing environments. It integrates laser-assisted bioprinting and extrusion technologies within a Class II Biosafety Cabinet, designed for aseptic clinical production of tissues such as skin substitutes.

3PickCell™ Module
CategoryBioprinting Add-on Module
Description

An image-guided, automated pick-and-place module for spheroid bioprinting that uses computer-vision algorithms to select spheroids based on morphology and programmatically position them to build layered or patterned tissue constructs with high reproducibility.

4ViewPrint™ Module
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Technology platform collaboration for evaluating NGB platform capabilities and tissue bioprinting advancements. Validation of PickCell technology integration and NGB platform compatibility with Fugu confinement systems developed by 3d.FAB for sterile bioproduction.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-03-28
Description

Distribution partnership for Poietis' NGB-R bioprinting platform in Austria and Germany. HVD Life Science provides local market access and support for tissue engineering and regenerative medicine R&D customers, bringing cutting-edge bioprinting technology to the forefront of biomedical research in these markets.

34-DBR (4-Deep Brain Reconstruction)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-31
Description

Horizon European Innovation Council (EIC) Pathfinder Open project for revolutionizing treatment of neurodegenerative disorders. Collaborative effort to develop conceptually novel approach for brain reconstruction providing groundbreaking solution for patients with conditions having limited treatment options.

poietis.com
4Assistance Publique – Hôpitaux de Marseille (AP-HM)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-24
Description

First installation of NGB bioprinting platform in hospital ATMP manufacturing area. Partnership for Phase I clinical trial of bioprinted skin substitute (Poieskin) for wound healing. AP-HM's Cell Culture and Therapy Laboratory has GMP manufacturing authorization and expertise for producing cell therapy preparations.

poietis.com
5Assistance Publique – Hôpitaux de Marseille (AP-HM)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-20
Description

Clinical research collaboration contract for Phase I clinical trial of bioprinted tissue engineering product for wound skin healing. Partnership combines Poietis' bioprinting technology with AP-HM's manufacturing authorization and clinical trial expertise in Advanced Therapy Medicinal Products.

poietis.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-12-19
Description

Scientific partnership for 4D bioprinting of liver tissues to develop and produce liver tissues for improved detection of drug-induced liver lesions in preclinical trials. Partnership creates complex bioprinted human liver tissue containing liver cell lines and immunocompetent cells within a defined architecture imitating human liver tissue in vitro.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-06-19
Description

2-year Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered ATMPs for skeletal regeneration. Combines Prometheus' cell-based technologies with Poietis' bioprinting technology to treat non-healing large cartilage and bone defects. Aims to develop automated GMP-compliant manufacturing processes for tissue implants.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

R&D partnership focused on refining bioprinted skin models for ingredient testing. Collaboration validated superiority of laser bioprinting for morphological accuracy and standardized signaling compared to conventional skin models in dermo-cosmetics and pharmaceutical applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic research partnership targeting biological complexity, specifically bioprinting of hair follicles - a major tissue engineering challenge requiring absolute precision in cellular positioning. Collaboration aims to advance understanding of skin and hair biology.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic partnership with Stäubli, global leader in sterile environment robotics, to power NGB platforms. TX2 6-axis robot specifically adapted for pharmaceutical use offers unsurpassed trajectory precision essential for Laser-Assisted Bioprinting technology and GMP compliance.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in bioprinting hardware, bioinks, and lab automation. Competes directly with Poietis across research bioprinters, tissue models, and consumables for pharma/cosmetics R&D customers, but at significantly larger scale and broader product portfolio.

TypeDirect peer
Description

Pioneer in 3D bioprinted human tissues for preclinical research and therapeutic applications. Closely comparable technology and use cases (bioprinted liver, skin, kidney tissues), though Organovo has shifted focus away from bioprinter hardware toward disease modeling and drug discovery services.

3Aspect Biosystems
TypeDirect peer
Description

Canada-based microfluidic 3D bioprinting company developing tissue therapeutics (e.g., pancreatic tissue for diabetes). Comparable in producing high-resolution tissue constructs for clinical applications and partnering with pharma, with a similar profile of strategic alliances and Series-stage funding.

TypeDirect peer
Description

Swiss developer of multi-modal bioprinters (3DDiscovery) combining extrusion, inkjet, and laser-assisted heads on robotic platforms. Most direct hardware competitor to the NGB platform, targeting similar research and translational tissue engineering customers.

TypeEmerging player
Description

German manufacturer of piezoelectric and microvalve bioprinters (BioScaffolder) and microfluidic instrumentation. Competes in the same research-tooling niche as NGB-R, particularly in European academic and pharma R&D accounts.

TypeEmerging player
Description

Australia-based developer of the Rastrum digital bioprinter for 3D cell culture and disease models. Comparable as a next-generation bioprinting platform focused on pharma/biology research use cases rather than implantable tissue manufacturing.

TypeEmerging player
Description

Berlin-based organ-on-chip company developing multi-organ microphysiological systems for drug testing. Highly comparable end-customer use case (preclinical pharma testing replacing animal models), though addressing it via microfluidic chips rather than laser-bioprinted tissue constructs.

TypeBroad incumbent
Description

Major industrial 3D printing incumbent with a healthcare vertical spanning surgical planning models, patient-specific implants, and bioprinting R&D. Broader portfolio and much larger installed base than Poietis, but overlapping end-customers in regenerative medicine.

TypeBroad incumbent
Description

Global polymer 3D printing leader with healthcare applications including anatomical models and orthopedic devices. Adjacent rather than direct bioprinting competitor, but a potential broad-incumbent threat as it extends into regenerative medicine and bioprinting-adjacent workflows.

TypeBroad incumbent
Description

Belgium-based 3D printing services and software provider with deep medical vertical (personalized surgical guides, implants, anatomical models). Comparable in serving patient-specific medical manufacturing and overlapping with Poietis' hospital/clinical translation ambitions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Poietis

Bioprinting Equipment and Tissue Engineeringpoietis.com

Poietis is a French biotechnology company that develops laser-assisted bioprinting platforms (NGB-R for research, NGB-C for clinical/GMP use) and the Poieskin bioprinted skin substitute, serving pharmaceutical, dermo-cosmetic, and hospital ATMP customers including BASF, L'Oréal, Servier, and AP-HM.

What Poietis does

Poietis is a French biotechnology company founded in 2014 in Pessac (Bordeaux Métropole) that develops and commercializes laser-assisted bioprinting (LAB) platforms for fabricating living human tissue. Its core technology is rooted in Laser-Induced Forward Transfer (LIFT), licensed exclusively from Inserm and the University of Bordeaux, and delivers picoliter-scale, nozzle-free cell deposition with >95% post-print viability at cellular resolution (10–50 µm). The company's flagship offering is the NGB (Next Generation Bioprinting) platform, available in two versions: NGB-R for research use and NGB-C, a GMP-compliant, Class II biosafety-cabinet-integrated system for clinical manufacturing of implantable tissues. The platform combines laser, extrusion, microvalve, and UV polymerization heads on a Stäubli 6-axis robotic arm, with optional add-on modules (PickCell for image-guided spheroid pick-and-place and ViewPrint for in-line microscope-based adaptive patterning). Poietis also sells Poieskin, positioned as the first commercially available bioprinted human skin substitute.

Poietis operates a multi-revenue-stream business model: capital equipment sales (NGB-R and NGB-C bioprinters under quote-based enterprise contracts), one-time sale of bioprinted tissue products (Poieskin), licensing/royalties on its licensed Inserm/University of Bordeaux technology, and fee-for-service research collaborations. Its go-to-market combines direct enterprise sales with event-driven demand generation at TERMIS, ISBF, and Biofabrication conferences, and selective channel distribution (HVD Life Science for Austria and Germany). The company is organized to serve pharmaceutical and dermo-cosmetic R&D buyers (BASF, L'Oréal, Servier), hospital ATMP manufacturers (AP-HM Marseille — site of the world's first GMP bioprinter installation), and academic research consortia (KU Leuven Prometheus, 3d.FAB). The firm is privately held, backed by approximately €6 million in disclosed equity and non-dilutive funding, employs 30–35 people, and operates a portfolio of 70+ patents.

Poietis firmographics

Firmographics
Name
Poietis
Legal name
Poietis SAS
Website
https://poietis.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Poietis is a French biotechnology company that develops laser-assisted bioprinting platforms (NGB-R for research, NGB-C for clinical/GMP use) and the Poieskin bioprinted skin substitute, serving pharmaceutical, dermo-cosmetic, and hospital ATMP customers including BASF, L'Oréal, Servier, and AP-HM.
Ownership category
akta.pro rank

Poietis industry classification

Industry
Product category
Bioprinting Equipment and Tissue Engineering
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAADAG
Medical & Dental 3D Printing Services (patient-specific devices, dental labs)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Services (On-Demand Manufacturing & Service Bureaus)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Laser-assisted bioprinting
  • 3D tissue engineering
  • Bioprinting platforms
  • Regenerative medicine
  • In vitro tissue models

Where Poietis is headquartered

Location

Headquarters

HQ city
Pessac
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Poietis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Bioprinter Sales (NGB-R and NGB-C): Sale of NGB bioprinting platforms - both research version (NGB-R) for academic and pharmaceutical R&D, and clinical version (NGB-C) for hospitals and cell therapy manufacturing centers. Revenue from capital equipment sales with typical enterprise sales cycle.
  2. Bioprinted Tissue Products (Poieskin): Sale of bioprinted tissue products including Poieskin, the first commercially available bioprinted human tissue. Used by pharmaceutical companies for drug testing and cosmetics companies for ingredient testing.
  3. Technology Licensing: Exclusive worldwide license to bioprinting technology developed at Inserm and University of Bordeaux. Technology licensing for commercial applications in tissue engineering and regenerative medicine.
  4. Research Partnerships and Collaborations: Fee-for-service research collaborations with pharmaceutical and cosmetic companies for development of specific tissue models, toxicology testing, and drug discovery applications.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Poietis product offering

Product offering

Core offering

Poietis designs and manufactures the NGB (Next Generation Bioprinting) robotic bioprinting platform available in two versions: NGB-R for research applications and NGB-C for clinical/GMP-compliant manufacturing of implantable tissues. The platform integrates laser-assisted bioprinting with extrusion, microvalve, and UV-curing technologies on a 6-axis robotic arm. Poietis also produces Poieskin, the first commercially available bioprinted human tissue product used for pharmaceutical testing, cosmetics evaluation, and clinical wound healing applications.

Product overview

Poietis offers a modular bioprinting platform architecture anchored by the NGB (Next Generation Bioprinting) system, available in two versions: NGB-R™ for research use and NGB-C™ for clinical/GMP manufacturing. The platform is multimodal, combining laser-assisted bioprinting (LAB) with extrusion, microvalve, and UV-curing heads on a robotic 6-axis arm, and supports add-on modules including ViewPrint™ (in-line microscope for real-time pattern adaptation) and PickCell™ (image-guided spheroid pick-and-place). The commercial tissue product Poieskin® — the first bioprinted tissue to reach the market — is produced using this technology. The portfolio spans from in vitro tissue models for pharmaceutical and dermo-cosmetic testing to implantable Advanced Therapy Medicinal Products (ATMPs) for regenerative medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • NGB (Next Generation Bioprinting): Multimodal bioprinting platform available in research (NGB-R) and clinical (NGB-C) versions, integrating laser, extrusion, and microvalve bioprinting technologies.
  • Poieskin
  • PickCell
  • ViewPrint

Products and services

  • NGB-R™ (Next Generation Bioprinting – Research) A robotic bioprinting platform for research applications in oncology, 3D tissue disease models, and translational research. It combines laser-assisted bioprinting (LAB) with extrusion and microvalve heads, a 6-axis robotic arm, and an in-line microscope, enabling high-precision, automated 3D tissue fabrication with cellular resolution.
  • NGB-C™ (Next Generation Bioprinting – Clinical) A GMP-compliant, clinical-grade robotic bioprinting platform for manufacturing implantable bioprinted tissues in hospital ATMP manufacturing environments. It integrates laser-assisted bioprinting and extrusion technologies within a Class II Biosafety Cabinet, designed for aseptic clinical production of tissues such as skin substitutes.
  • PickCell™ Module An image-guided, automated pick-and-place module for spheroid bioprinting that uses computer-vision algorithms to select spheroids based on morphology and programmatically position them to build layered or patterned tissue constructs with high reproducibility.
  • ViewPrint™ Module

Quantifiable outcome

  • Cell viability post-printing maintained above 95%
  • +3 more outcomes

Companies that use Poietis

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Poietis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Poietis partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • 3d.FABminorStrategic or Co-development Partner · 23 March 2026Technology platform collaboration for evaluating NGB platform capabilities and tissue bioprinting advancements. Validation of PickCell technology integration and NGB platform compatibility with Fugu confinement systems developed by 3d.FAB for sterile bioproduction.
  • HVD Life SciencecoreChannel Partner/ Reseller/ Distributor · 28 March 2024Distribution partnership for Poietis' NGB-R bioprinting platform in Austria and Germany. HVD Life Science provides local market access and support for tissue engineering and regenerative medicine R&D customers, bringing cutting-edge bioprinting technology to the forefront of biomedical research in these markets.
  • 4-DBR (4-Deep Brain Reconstruction)coreStrategic or Co-development Partner · 31 January 2024Horizon European Innovation Council (EIC) Pathfinder Open project for revolutionizing treatment of neurodegenerative disorders. Collaborative effort to develop conceptually novel approach for brain reconstruction providing groundbreaking solution for patients with conditions having limited treatment options.
  • Assistance Publique – Hôpitaux de Marseille (AP-HM)coreStrategic or Co-development Partner · 24 November 2021First installation of NGB bioprinting platform in hospital ATMP manufacturing area. Partnership for Phase I clinical trial of bioprinted skin substitute (Poieskin) for wound healing. AP-HM's Cell Culture and Therapy Laboratory has GMP manufacturing authorization and expertise for producing cell therapy preparations.
  • Assistance Publique – Hôpitaux de Marseille (AP-HM)coreStrategic or Co-development Partner · 20 January 2020Clinical research collaboration contract for Phase I clinical trial of bioprinted tissue engineering product for wound skin healing. Partnership combines Poietis' bioprinting technology with AP-HM's manufacturing authorization and clinical trial expertise in Advanced Therapy Medicinal Products.
  • ServiercoreStrategic or Co-development Partner · 19 December 2018Scientific partnership for 4D bioprinting of liver tissues to develop and produce liver tissues for improved detection of drug-induced liver lesions in preclinical trials. Partnership creates complex bioprinted human liver tissue containing liver cell lines and immunocompetent cells within a defined architecture imitating human liver tissue in vitro.
  • Prometheus (KU Leuven)coreStrategic or Co-development Partner · 19 June 20182-year Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered ATMPs for skeletal regeneration. Combines Prometheus' cell-based technologies with Poietis' bioprinting technology to treat non-healing large cartilage and bone defects. Aims to develop automated GMP-compliant manufacturing processes for tissue implants.
  • BASFcoreStrategic or Co-development PartnerR&D partnership focused on refining bioprinted skin models for ingredient testing. Collaboration validated superiority of laser bioprinting for morphological accuracy and standardized signaling compared to conventional skin models in dermo-cosmetics and pharmaceutical applications.
  • L'OréalcoreStrategic or Co-development PartnerStrategic research partnership targeting biological complexity, specifically bioprinting of hair follicles - a major tissue engineering challenge requiring absolute precision in cellular positioning. Collaboration aims to advance understanding of skin and hair biology.
  • StäublicoreTechnology or IntegrationStrategic partnership with Stäubli, global leader in sterile environment robotics, to power NGB platforms. TX2 6-axis robot specifically adapted for pharmaceutical use offers unsurpassed trajectory precision essential for Laser-Assisted Bioprinting technology and GMP compliance.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Poietis competitors and assessment

Company assessment

Direct peers

  • BICO (formerly Cellink): Global leader in bioprinting hardware, bioinks, and lab automation. Competes directly with Poietis across research bioprinters, tissue models, and consumables for pharma/cosmetics R&D customers, but at significantly larger scale and broader product portfolio.
  • Organovo: Pioneer in 3D bioprinted human tissues for preclinical research and therapeutic applications. Closely comparable technology and use cases (bioprinted liver, skin, kidney tissues), though Organovo has shifted focus away from bioprinter hardware toward disease modeling and drug discovery services.
  • Aspect Biosystems: Canada-based microfluidic 3D bioprinting company developing tissue therapeutics (e.g., pancreatic tissue for diabetes). Comparable in producing high-resolution tissue constructs for clinical applications and partnering with pharma, with a similar profile of strategic alliances and Series-stage funding.
  • regenHU: Swiss developer of multi-modal bioprinters (3DDiscovery) combining extrusion, inkjet, and laser-assisted heads on robotic platforms. Most direct hardware competitor to the NGB platform, targeting similar research and translational tissue engineering customers.

Emerging players

  • GeSiM: German manufacturer of piezoelectric and microvalve bioprinters (BioScaffolder) and microfluidic instrumentation. Competes in the same research-tooling niche as NGB-R, particularly in European academic and pharma R&D accounts.
  • Inventia Life Science: Australia-based developer of the Rastrum digital bioprinter for 3D cell culture and disease models. Comparable as a next-generation bioprinting platform focused on pharma/biology research use cases rather than implantable tissue manufacturing.
  • TissUse: Berlin-based organ-on-chip company developing multi-organ microphysiological systems for drug testing. Highly comparable end-customer use case (preclinical pharma testing replacing animal models), though addressing it via microfluidic chips rather than laser-bioprinted tissue constructs.

Broad incumbents

  • 3D Systems: Major industrial 3D printing incumbent with a healthcare vertical spanning surgical planning models, patient-specific implants, and bioprinting R&D. Broader portfolio and much larger installed base than Poietis, but overlapping end-customers in regenerative medicine.
  • Stratasys: Global polymer 3D printing leader with healthcare applications including anatomical models and orthopedic devices. Adjacent rather than direct bioprinting competitor, but a potential broad-incumbent threat as it extends into regenerative medicine and bioprinting-adjacent workflows.
  • Materialise: Belgium-based 3D printing services and software provider with deep medical vertical (personalized surgical guides, implants, anatomical models). Comparable in serving patient-specific medical manufacturing and overlapping with Poietis' hospital/clinical translation ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Poietis social profiles

Digital presence

Poietis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Poietis leadership team

Management profile

Number of profiles

Profiles5 records

Poietis funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Poietis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Poietis

What does Poietis do?

Poietis designs and manufactures the NGB (Next Generation Bioprinting) robotic bioprinting platform available in two versions: NGB-R for research applications and NGB-C for clinical/GMP-compliant manufacturing of implantable tissues. The platform integrates laser-assisted bioprinting with extrusion, microvalve, and UV-curing technologies on a 6-axis robotic arm. Poietis also produces Poieskin, the first commercially available bioprinted human tissue product used for pharmaceutical testing, cosmetics evaluation, and clinical wound healing applications.

Is Poietis a public or private company?

Poietis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Poietis founded?

Poietis was founded in 2014. It employs 11 to 50 people.

Where is Poietis based?

Poietis is headquartered in Pessac, France, in the Europe region.

How does Poietis make money?

Four revenue lines are on record. Bioprinter Sales (NGB-R and NGB-C) is the primary driver. The others are bioprinted Tissue Products (Poieskin), technology Licensing and research Partnerships and Collaborations.

Who are Poietis's main competitors?

Direct peers on record are BICO (formerly Cellink), Organovo, Aspect Biosystems and regenHU. Emerging players are GeSiM, Inventia Life Science and TissUse. Broad incumbents are 3D Systems, Stratasys and Materialise.

Does Poietis have an API?

No public API is recorded for Poietis.

What industry is Poietis in?

Poietis's product category is Bioprinting Equipment and Tissue Engineering. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-Medical3D bioprinting for organoid and tissue developmentThe article discusses advances in bioprinting technologies used to develop organoids and cartilaginous spheroids, focusing on laser-assisted bioprinting techniques such as LAB, LIFT, and LIPMO. It highlights the capabilities of these methods in precision tissue engineering and the development of larger spheroids with high viability. The Next Generation Bioprinting System (NGB-R) by Poietis is introduced as a versatile platform combining multiple bioprinting methods for research purposes.openPR.com3D Bioprinting Market - Global Industry Analysis, Trends & Forecast (2024-2032)Acumen Research and Consulting released a comprehensive market analysis projecting the global 3D bioprinting market will grow from USD 1.92 billion in 2023 to USD 7.33 billion by 2032, representing a compound annual growth rate of 16.3%. The report identifies key growth drivers including rising demand for organ transplants, technological advancements in bio-inks and materials, and increasing investments in regenerative medicine and drug discovery applications. North America currently leads the market, while Asia-Pacific is projected to be the fastest-growing region, with the industry competitive landscape featuring companies such as Organovo Holdings Inc., CELLINK (BICO Group), and Poietis.Cosmetics BusinessL’Oréal and Poietis aim to create bioprinted hair folliclesL'Oréal and Poietis announced a partnership to bioprint hair follicles, aiming to address hair loss. The collaboration involves Poietis' 3D tissue modeling and L'Oréal's hair biology expertise. The initiative targets creating functional hair follicles for regenerative applications.Cosmetics BusinessBASF and Poietis sign 3D skin printing dealBASF and Poietis signed a cosmetics R&D agreement to apply Poietis' 3D laser-assisted bioprinting technology to BASF's skin model Mimeskin. The partnership aims to automate Mimeskin reproduction and develop advanced models with additional cell types, offering an alternative to animal testing in cosmetics.Slate MagazineWhat do biohackers have to do with your skin care routine? More than you know.This essay explores how biohacking technology developed at conferences like BDYHAX and through government-backed research is influencing the commercial beauty and skincare industry. Companies including Skincential Sciences (with CIA-funded DNA extraction technology), L'Oréal (spending over 1.2 billion euros on research in 2023), and startups like OneSkin and Poietis are converging around anti-aging and bioprinting innovations. The author examines the ethical implications of these technologies while highlighting billionaires including Jeff Bezos, Peter Thiel, and Elon Musk who have invested heavily in transhumanist and longevity ventures.Cosmetics BusinessBASF and Poietis sign a research and development agreement on 3D bio-printing technologyBASF and Poietis signed an R&D agreement to apply Poietis' 3D laser-assisted bio-printing to BASF's skin model Mimeskin. The partnership aims to automate Mimeskin reproduction and develop advanced models with additional cell types, supporting cosmetic bio-actives testing.ScinticaThe Role of 3D Bioprinting in 3D Tissue Modeling and Emerging Medical TherapiesThis article provides an overview of 3D bioprinting technology and its applications in regenerative medicine, tissue engineering, drug testing, and pharmaceutical development. It highlights Poietis' NGB-R Next-Generation Bioprinting platform as a multimodal solution combining laser-assisted bioprinting, bio-extrusion, and micro-valve techniques with a 6-axis robotic arm for precision tissue fabrication. The article discusses emerging applications including skin regeneration, ophthalmology, organ regeneration, and advanced tissue modeling, while promoting Scintica as a distributor of this technology.Global-Imi7 Ways We Benefit from 3D BioprintingAn explainer article outlines how 3D bioprinting uses patient cells, bioink and biomaterials to print living tissues and organs, noting that printing takes hours while implantation testing takes at least a month. It cites milestones including a 90-day bioprinted mini liver, a 2022 bioprinted cornea transplanted in a rabbit, a 3DBio Therapeutics printed ear, a Toulouse University Hospital nasal reconstruction, and Poietis' Poieskin skin model.National Center for Biotechnology Information3D Bioprinting: The Roller Coaster Ride to CommercializationA review article examines 3D bioprinting, a layer-by-layer fabrication of tissue constructs using living cells, noting its research since 2003 and limited commercialization. It covers in situ bioprinting, space experiments, drug discovery and food applications, and emerging magnetic and acoustic bioprinting. It cites Poietis' planned Phase I skin trial and a $1 billion skin bioprinting market estimate by 2024.WebWireBASF and Poietis sign new agreement on 3D bioprinting technologyBASF and Poietis signed a framework agreement to further develop 3D laser-assisted bioprinting technology for skin models. The models, co-developed since 2015, can be produced in two weeks to evaluate cosmetic ingredients. BASF plans to develop and market active ingredients based on the collaboration.